Now open access in NDT Obinutuzumab versus RTX for refractory primary membranous nephropathy 🧐This retrospective study suggests that OBI is an effective option for pts with prim. MGN refractory to GC+CTX, CNI, and RTX regimen. ▶️academic.oup.com/ndt/article/do……

Congratulations to Philipp Gauckler and Andreas Kronbichler for leading this important study of rituximab in podocytopathies. It was a real multi-centre effort with important results for clinical practice. See this very useful thread below 👇🏻

The YNP of ERA board meeting in Parma, Italy was a fantastic brainstorming about current and exciting future projects. Fernando Caravaca-Fontán and Michele Eisenga were online with us! Stay tuned about our activities via ERA - European Renal Association website: era-online.org/research-educa…

It was my pleasure and a great experience to discuss the role of plasma exchange in #AAV at the Ohio State Nephrology. Brilliant fellows and a surprise visit by Lynn Fussner. Thank you Salem Almaani, Brad H Rovin and Jessica Greco for the wonderful hosting!

Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) nej.md/3UmrOkh Editorial: Waystations in Progress — Burgeoning Treatment Options for IgA Nephropathy nej.md/4fdz9dV #KidneyWk | American Society of Nephrology

Original Article: Atrasentan in Patients with IgA Nephropathy (ALIGN) nej.md/3NzvISW Editorial: Waystations in Progress — Burgeoning Treatment Options for IgA Nephropathy nej.md/4fdz9dV #KidneyWk | American Society of Nephrology

🔥 Our snapshot summary on a survey study on what patients with CKD actually want to know! doi.org/10.1093/ckj/sf… Jet Milders is the YNP author. Prepared by Lauren Floyd. ERA - European Renal Association CKJ

👀 Check our new snapshot summary on fluid removal targets during intermittent renal replacement therapy for AKI! doi.org/10.1093/ckj/sf… @WBeaubien is the YNP author. Prepared by Safak Mirioglu. ERA - European Renal Association CKJ

Website's up! vasculitis-melbourne2026.com All things #vasculitis in Melbourne Feb 2026. Key dates, things to do and promotional tools, with more to follow Come for exceptional research, learning and interactions over 5 days And....a great trip to Australia and New Zealand!

Lupus nephritis: redefining the treatment goals doi.org/10.1016/j.kint… #KIEditorial #OpenAccess #lupusnephritis Mayo Clinic Nephrology Mayo Clinic Pathology

✅ Let's see who will bring forward the best arguments 😏😇 #Lupus nephritis - standard of care (for all, will already be something)

The effects of #plasmaexchange and #glucocorticoids on early kidney function among patients with #ANCA-associated #vasculitis in the PEXIVAS trial doi.org/10.1016/j.kint… #OpenAccess #glomerulonephritis #ESKD

Check out our newest paper on a practical approach to common nephrology consultations. 👇🏻 Great job Michael Kolland, Simon Aberger , Alexander Kirsch ! 👌🏻 academic.oup.com/ckj/advance-ar…

1/ New thread on recently published CKJ paper by Luis Harrison using target trial emulation to assess impact of arteriovenous fistula 🩸 formation on kidney function decline 📉 Link 👉 doi.org/10.1093/ckj/sf… 🧵by Richard Shemilt

📢 Join us at the YNP & EFIM joint e-seminar: *Cardiorenal Syndrome – Perspectives from Nephrology and Internal Medicine* 📅 Wednesday, May 14, 2025, 5:00 PM (CEST) Register now 👉 bit.ly/4jXCuQA

We’re calling on researchers, clinicians, and educators—share your work with the global vasculitis community! Submit your abstract by 19 September 2025—don’t miss your chance to be part of this exciting event! vasculitis-melbourne2026.com/call-for-abstr… #VasculitisMelbourne2026

ANCA-negative pauci-immune glomerulonephritis must be one of the most challenging fields in vasculitis. In this commentary in KIReports, we discuss some open questions on this topic. kireports.org/article/S2468-…